| Previous Section | Index | Home Page |
20 Jan 2006 : Column 1654W—continued
Veterans' Badges
Mr. Paul Murphy: To ask the Secretary of State for Defence how many veterans' badges have been issued since the badge was introduced. [44492]
Mr. Touhig: The veterans' badge scheme was launched in May 2004 and, to date, some 182,000 ex-Service personnel have applied for and received the badge.
HEALTH
Abortions
Mr. Amess: To ask the Secretary of State for Health what steps her Department plans to take to reduce the number of abortions in each of the next five years; and if she will make a statement. [41634]
Caroline Flint: For information on action being taken to reduce the number of abortions, I refer the hon. Member to the answer I gave on 21 July 2005, Official Report, column 2142W.
Improving access to contraception was identified as a priority area in the Choosing Health White Paper. An extra £40 million for primary care trusts has been provided for the next two years. We are currently carrying out a national audit of contraceptive services, which we aim to publish in the spring. We are also working with the Healthcare Commission to see what further steps might be taken to improve the local delivery of teenage pregnancy prevention, contraceptive and abortion services as part of a wider programme of improvement of sexual health services.
Acute Trusts
Dr. Pugh: To ask the Secretary of State for Health whether each acute trust which is in deficit has engaged in self-commissioning activity above the value of £10,000 over the last five years. [34914]
Mr. Byrne: Acute trusts do not self-commission.
Mr. Maude: To ask the Secretary of State for Health what the average length of stay was for patients in (a) acute trusts, (b) Surrey and Sussex health authority area and (c) England in the last year for which figures are available. [35154]
Mr. Byrne:
The data requested are shown in the table.
20 Jan 2006 : Column 1655W
Notes:
1. The mean length of stay in (b1) is based on the patients that were resident in Surrey and Sussex Strategic Health Authority (SHA) area and (b2) is based on the patients that were treated in Surrey and Sussex SHA area.
2. A length of spell is defined as a period of in-patient care within one health care provider that commences with the patient's admission and ends on the date of discharge. It may comprise of one or more finished consultant episodes.
3. A length of stay (LOS) is calculated as the difference in days between the admission date and the discharge date, where both are given. LOS is based on hospital spells and only applies to ordinary admissions, i.e. day cases are excluded. Information relating to LOS figures, including discharge method or destination, diagnoses and any operative procedures, is based only on the final episode of the spell.
4. Figures have not been adjusted for shortfalls in data, that is, the data is ungrossed.
Source:
Hospital Episode Statistics, NHS Health and Social Care Information Centre
20 Jan 2006 : Column 1656W
Alcohol Data
Mr. Lansley: To ask the Secretary of State for Health pursuant to the answer of 19 December 2005, Official Report, column 2600W, on alcohol, (1) for what reasons data for 2004–05 were omitted; and if she will publish the data for 2004–05 on counts of finished consultant episodes; [41956]
(2) pursuant to the answer of 19 December 2005, Official Report, column 2603W, on alcohol, for what reasons data for 2004–05 were omitted; and if she will publish the data for 2004–05 on counts of finished admission episodes. [41957]
Caroline Flint: The information requested is shown in the table. I regret that my previous reply was incomplete.
(17) Alcohol related diseases defined as following ICD-10 codes recorded in primary diagnosis:
F10: Mental and behavioural disorders due to use of alcohol
K70: Alcoholic liver disease
T51: Toxic effect of alcohol
NHS Hospitals, England 2004–05
20 Jan 2006 : Column 1657W
Alcohol Licensing
Mr. Amess: To ask the Secretary of State for Health whether the exemption under Part 1, Clause 3, sub-section (2)(b) of the proposed Health Bill will apply to bingo club premises holding a premises licence under the Licensing Act 2003 allowing the consumption of alcohol on the premises, providing that food is not supplied. [28148]
Caroline Flint: The very specific circumstances of a bingo club as described in the question are not detailed on the face of the Bill.
We will give this point due consideration in drafting regulations.
Alzheimer's Disease
Clive Efford: To ask the Secretary of State for Health (1) when she expects to receive the recommendation of the National Institute for Health and Clinical Excellence relating to (a) Donepezil, (b) Rivastigmine, (c) Galantamine and (d) Memantine; and if she will make a statement; [42203]
(2) pursuant to the answer of 29 November 2005, Official Report, column 398W, on Alzheimer's disease, what discussions she has had with the National Institute for Health and Clinical Excellence since her meeting of 9 June regarding appraisal of drugs for the treatment of Alzheimer's disease; [42204]
(3) what estimate she has made of the annual cost of treating a patient suffering from Alzheimer's disease with (a) Donepezil, (b) Rivastigmine, (c) Galantamine and (d) Memantine. [42205]
Jane Kennedy: The National Institute for Health and Clinical Excellence (NICE) communicated the decision of its appraisal committee to consultees, including the Department, under NICE's normal rules of confidentiality on 16 January 2006. This communication will be published on its website on 23 January, at www.nice.org.uk.
Since 9 June 2005, I have had no further meetings with NICE regarding its appraisal of drugs for the treatment of Alzheimer's disease. However, I received a brief factual update from the chairman of NICE when I met him at the NICE annual conference on 7 December 2005.
NICE'S Appraisal "Consultation Document on drugs for Alzheimer's disease" (March 2005) suggested that the cost of a year's supply of each of these four drugs is:
| £ | |
|---|---|
| Donepezil | (18)828.30 to 1,160.96 |
| Rivastigmine | 886.95 |
| Galantamine | (18)890.60 to £1,095 |
| Memantine | 899.54 |
(18) Depending on dose
These costs are based on prices published in the British National Formulary and exclude value added tax. Costs may vary in different settings because of negotiated procurement discounts.
20 Jan 2006 : Column 1658W
| Next Section | Index | Home Page |